hemat

  1. T

    Affymax And Takeda Confirm U.S. Registration Strategy For Investigational Drug, Hemat

    Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE, 4502), announced that following pre-New Drug Application (NDA) discussions with the U.S. Food and Drug Administration (FDA), the companies will move forward with their regulatory strategy for the investigational drug...
Back
Top